Company Profile

in November 2018, BioTime Inc. re-acquired an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 16.2%. BioTime Inc, is a biotechnology company focused on biomedical research and product development in the field of regenerative medicine: specifically, new therapeutics for age-related degenerative disease. Based on stem cell technology, BioTime's regenerative medicine therapies are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Focused on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells which provide a means to manufacture every type of cell in the human body, BioTime’s HyStem hydrogels represent a core enabling technology for regenerative medicine and cellular delivery and are used by researchers worldwide for tissue engineering, 2D and 3D cell culture, and disease models. HyStem is a biomaterial that mimics the human extracellular matrix, a network of molecules surrounding cells in organs and tissues which is essential to cellular function. HyStem hydrogels may have other applications when combined with cell types BioTime scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's subsidiaries include various regenerative medicine companies developing novel tr